400 related articles for article (PubMed ID: 18922022)
41. HU-331 is a catalytic inhibitor of topoisomerase IIα.
Regal KM; Mercer SL; Deweese JE
Chem Res Toxicol; 2014 Dec; 27(12):2044-51. PubMed ID: 25409338
[TBL] [Abstract][Full Text] [Related]
42. Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
Zwelling LA; Chan D; Hinds M; Mayes J; Silberman LE; Blick M
Cancer Res; 1988 Dec; 48(23):6625-33. PubMed ID: 2846155
[TBL] [Abstract][Full Text] [Related]
43. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells.
Sullivan DM; Latham MD; Ross WE
Cancer Res; 1987 Aug; 47(15):3973-9. PubMed ID: 3038304
[TBL] [Abstract][Full Text] [Related]
44. Chiral ruthenium(II) complexes with phenolic hydroxyl groups as dual poisons of topoisomerases I and IIα.
Zhang P; Wang J; Huang H; Qiao L; Ji L; Chao H
Dalton Trans; 2013 Jun; 42(24):8907-17. PubMed ID: 23661230
[TBL] [Abstract][Full Text] [Related]
45. Spontaneous DNA lesions poison human topoisomerase IIalpha and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints.
Kingma PS; Greider CA; Osheroff N
Biochemistry; 1997 May; 36(20):5934-9. PubMed ID: 9166762
[TBL] [Abstract][Full Text] [Related]
46. N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIα and induce apoptosis in G1/S phase.
Baviskar AT; Madaan C; Preet R; Mohapatra P; Jain V; Agarwal A; Guchhait SK; Kundu CN; Banerjee UC; Bharatam PV
J Med Chem; 2011 Jul; 54(14):5013-30. PubMed ID: 21644529
[TBL] [Abstract][Full Text] [Related]
47. DNA sequence specificity for topoisomerase II poisoning by the quinoxaline anticancer drugs XK469 and CQS.
Gao H; Yamasaki EF; Chan KK; Shen LL; Snapka RM
Mol Pharmacol; 2003 Jun; 63(6):1382-8. PubMed ID: 12761349
[TBL] [Abstract][Full Text] [Related]
48. Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes.
Osheroff N; Corbett AH; Elsea SH; Westergaard M
Cancer Chemother Pharmacol; 1994; 34 Suppl():S19-25. PubMed ID: 8070023
[TBL] [Abstract][Full Text] [Related]
49. Two-Mechanism Model for the Interaction of Etoposide Quinone with Topoisomerase IIα.
Gibson EG; King MM; Mercer SL; Deweese JE
Chem Res Toxicol; 2016 Sep; 29(9):1541-8. PubMed ID: 27533850
[TBL] [Abstract][Full Text] [Related]
50. Dependence of etoposide-induced cytotoxicity and topoisomerase II-mediated DNA strand breakage on the intracellular ionic environment.
Lawrence TS; Canman CE; Maybaum J; Davis MA
Cancer Res; 1989 Sep; 49(17):4775-9. PubMed ID: 2547516
[TBL] [Abstract][Full Text] [Related]
51. Etoposide quinone is a covalent poison of human topoisomerase IIβ.
Smith NA; Byl JA; Mercer SL; Deweese JE; Osheroff N
Biochemistry; 2014 May; 53(19):3229-36. PubMed ID: 24766193
[TBL] [Abstract][Full Text] [Related]
52. Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance.
Kingma PS; Burden DA; Osheroff N
Biochemistry; 1999 Mar; 38(12):3457-61. PubMed ID: 10090731
[TBL] [Abstract][Full Text] [Related]
53. Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage.
Gentry AC; Pitts SL; Jablonsky MJ; Bailly C; Graves DE; Osheroff N
Biochemistry; 2011 Apr; 50(15):3240-9. PubMed ID: 21413765
[TBL] [Abstract][Full Text] [Related]
54. Bioassays and In Silico Methods in the Identification of Human DNA Topoisomerase IIα Inhibitors.
Bergant K; Janezic M; Perdih A
Curr Med Chem; 2018; 25(28):3286-3318. PubMed ID: 29508675
[TBL] [Abstract][Full Text] [Related]
55. Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme.
Corbett AH; Hong D; Osheroff N
J Biol Chem; 1993 Jul; 268(19):14394-8. PubMed ID: 8390992
[TBL] [Abstract][Full Text] [Related]
56. Stimulation of topoisomerase II-mediated DNA cleavage by benzene metabolites.
Lindsey RH; Bender RP; Osheroff N
Chem Biol Interact; 2005 May; 153-154():197-205. PubMed ID: 15935817
[TBL] [Abstract][Full Text] [Related]
57. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
[TBL] [Abstract][Full Text] [Related]
58. Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4'-(9-acridinylamino)methane-sulfon-m-anisidide.
DeVore RF; Corbett AH; Osheroff N
Cancer Res; 1992 Apr; 52(8):2156-61. PubMed ID: 1313738
[TBL] [Abstract][Full Text] [Related]
59. A two-drug model for etoposide action against human topoisomerase IIalpha.
Bromberg KD; Burgin AB; Osheroff N
J Biol Chem; 2003 Feb; 278(9):7406-12. PubMed ID: 12473657
[TBL] [Abstract][Full Text] [Related]
60. Etoposide-induced DNA cleavage in human leukemia cells.
Edwards CM; Glisson BS; King CK; Smallwood-Kentro S; Ross WE
Cancer Chemother Pharmacol; 1987; 20(2):162-8. PubMed ID: 2822274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
